

PRESS RELEASE

Gradientech publishes prospectus

Uppsala, Sweden, 4 March, 2026. **The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue is approved by the Swedish Financial Supervisory Authority be available on the Company's website [gradientech.se](https://www.gradientech.se).**

Prospectus

Complete terms and conditions for the Rights Issue as well as other information about the Company and information about subscription commitments appear in the prospectus that is available on the Company's and the Swedish Financial Supervisory Authority respective websites ([gradientech.se](https://www.gradientech.se), [fi.se](https://www.fi.se)).

Investor presentations

Shareholders are invited to participate in Gradientech’s investor presentations via Teams at the following times:

11 March, 11.00-11.30 CET

12 March, 17.00-17.30 CET

16 March, 15.00-15.30 CET

Links to the presentation events are available on the Company’s website [gradientech.se](https://www.gradientech.se).

For further information, please contact:

Sara Thorslund, CEO

Tel: + 46 763 29 35 80

sara.thorslund@gradientech.se

Urban Adolfsson, CFO

Tel: + 46 708 20 72 09

urban.adolfsson@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.